<DOC>
	<DOCNO>NCT01155934</DOCNO>
	<brief_summary>The purpose study ass single-dose relative bioavailability study 1 mg risperidone orally disintegrate tablet ( Risperdal M-TAB ) feed condition .</brief_summary>
	<brief_title>Bioavailability Study Risperidone Orally Disintegrating Tablets 1 mg Dr.Reddy 's Laboratories Limited Under Fed Conditions</brief_title>
	<detailed_description>Comparative , Randomized , Single-Dose , 2-way Crossover Bioavailability Study Dr Reddy 's Laboratories Ltd. Janssen Pharmaceutica Products , LP . ( Risperdal M-TAB ) 1 mg Risperidone Orally Disintegrating Tablets Healthy Adult Male Volunteers Fed Conditions</detailed_description>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subjects include study meet follow criterion : Healthy nonsmoking ( least 3 month ) adult male volunteer , 1845 year age ; Weighing least 60 kg male within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically normal laboratory profile ECGs ; Voluntarily consent participate study . Subjects exclude study evidence follow screening time study : History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction risperidone benzodiazepine antipsychotic drug ; seizure ; glaucoma hypermetropia . Positive result Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HbsAg ) Hepatitis C Virus ( HCV ) Tests . Subjects whose sit blood pressure le 110/60 mm Hg screen 100/55 mm Hg dosing . Subjects whose pulse low 55 b.p.m . screen 50 b.p.m . prior dosing . Subjects whose PR interval ≥ 190 msec screen prior dosing . Subjects whose aTe interval &gt; 450 msec screen prior dosing . Subjects body temperature ≥38°C dosing . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know cytochrome P450 enzyme ) within 10 day prior first dose . Subjects use drug substance know strong inducer CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects , completion study , would donate excess : 500 mL blood 14 day , 1500 mL blood 180 day , 2500 mL blood 1 year . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>Crossover</keyword>
	<keyword>Risperidone</keyword>
</DOC>